{"entity":{"id":"hospital-clinic-barcelona","kind":"institution","name":"Hospital Clínic de Barcelona / IDIBAPS","aka":["Hospital Clínic","IDIBAPS","Clínic Barcelona Comprehensive Cancer Center"],"tldr":"Barcelona's university hospital, home of the BCLC liver cancer staging system, the first European academic CAR-T and leading breast and lymphoma genomics.","summary":"Hospital Clínic and its research institute IDIBAPS form one of Spain's strongest academic medical centres. The Barcelona Clinic Liver Cancer group of Jordi Bruix and Josep Maria Llovet created the BCLC staging and treatment algorithm and led the SHARP trial that made sorafenib the first systemic therapy for hepatocellular carcinoma. Elías Campo's group mapped the genome of chronic lymphocytic leukaemia within the ICGC and co-edits the WHO haematolymphoid classification, Aleix Prat's group advanced intrinsic subtyping (PAM50, HER2DX) in breast cancer, and the hospital's ARI-0001 CD19 CAR-T, developed by Manel Juan and Álvaro Urbano-Ispizua, became the first academic CAR-T authorised in Europe under Spain's hospital exemption in 2021. The centre is OECI-accredited and runs a large early-phase and haematology programme.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.clinicbarcelona.org/en"},{"label":"IDIBAPS","url":"https://www.clinicbarcelona.org/en/idibaps"}],"tags":[],"related":[],"cancers":["hcc","cll","all-leukemia","breast-hr-positive","multiple-myeloma"],"sections":["cell-therapy","targeted-therapy"],"technologies":["car-t","rna-seq","wes-wgs","kinase-inhibitors"],"targets":["cd19","bcma"],"drugs":[],"companies":[],"institutions":["vall-dhebron","oeci"],"pathways":[],"terms":["pam50"],"trials":[],"people":["josep-maria-campistol","susana-puig","josep-llovet","aleix-prat"],"bottlenecks":["b-manufacturing-cell-therapy","b-drug-pricing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Barcelona","country":"ES","lat":41.389,"lng":2.152,"institutionType":"hospital","website":"https://www.clinicbarcelona.org/en","university":"Universitat de Barcelona","programs":["BCLC liver cancer group","Academic CAR-T (ARI-0001, ARI-0002h)","Lymphoid neoplasm genomics","Breast cancer intrinsic subtypes","Early-phase trials"]},"route":"/institutions/hospital-clinic-barcelona/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"},{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"},{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"institution":[{"id":"hospital-del-mar","kind":"institution","name":"Hospital del Mar / Hospital del Mar Research Institute","route":"/institutions/hospital-del-mar/"},{"id":"12-de-octubre","kind":"institution","name":"Hospital Universitario 12 de Octubre","route":"/institutions/12-de-octubre/"},{"id":"oeci","kind":"institution","name":"Organisation of European Cancer Institutes","route":"/institutions/oeci/"},{"id":"vall-dhebron","kind":"institution","name":"Vall d'Hebron University Hospital / VHIO","route":"/institutions/vall-dhebron/"}],"term":[{"id":"pam50","kind":"term","name":"PAM50 / intrinsic subtypes","route":"/terms/pam50/"}],"person":[{"id":"aleix-prat","kind":"person","name":"Aleix Prat","route":"/people/aleix-prat/"},{"id":"jordi-bruix","kind":"person","name":"Jordi Bruix","route":"/people/jordi-bruix/"},{"id":"josep-llovet","kind":"person","name":"Josep M. Llovet","route":"/people/josep-llovet/"},{"id":"josep-maria-campistol","kind":"person","name":"Josep Maria Campistol","route":"/people/josep-maria-campistol/"},{"id":"susana-puig","kind":"person","name":"Susana Puig","route":"/people/susana-puig/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"}],"paper":[{"id":"paper-moreira-lynch-syndrome-identification-jama-2012","kind":"paper","name":"Identification of Lynch syndrome among patients with colorectal cancer","route":"/key-papers/paper-moreira-lynch-syndrome-identification-jama-2012/"}]}}